Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections

Por Mueller-Loebnitz, Christoph, Ostermann, Helmut, Franzke, Anke, Loeffler, Juergen, Uharek, Lutz, Topp, Max, Einsele, Hermann
Publicado em 2013

Restoration of CD28 Expression in CD28(−) CD8(+) Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production

Por Topp, Max S., Riddell, Stanley R., Akatsuka, Yoshiki, Jensen, Michael C., Blattman, Joseph N., Greenberg, Philip D.
Publicado em 2003

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Por Stein, Anthony S., Schiller, Gary, Benjamin, Ramsis, Jia, Catherine, Zhang, Alicia, Zhu, Min, Zimmerman, Zachary, Topp, Max S.
Publicado no Ann Hematol (2018)

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78

Por Rasche, Leo, Duell, Johannes, Morgner, Charlotte, Chatterjee, Manik, Hensel, Frank, Rosenwald, Andreas, Einsele, Hermann, Topp, Max S., Brändlein, Stephanie
Publicado em 2013

Hsp90 inhibition ameliorates CD4(+) T cell‐mediated acute Graft versus Host disease in mice

Por Berges, Carsten, Kerkau, Thomas, Werner, Sandra, Wolf, Nelli, Winter, Nadine, Hünig, Thomas, Einsele, Hermann, Topp, Max S., Beyersdorf, Niklas
Publicado no Immun Inflamm Dis (2016)

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Por Topp, Max S., Zimmerman, Zachary, Cannell, Paul, Dombret, Hervé, Maertens, Johan, Stein, Anthony, Franklin, Janet, Tran, Qui, Cong, Ze, Schuh, Andre C.
Publicado no Blood (2018)

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Por Stein, Anthony S., Larson, Richard A., Schuh, Andre C., Stevenson, William, Lech-Maranda, Ewa, Tran, Qui, Zimmerman, Zachary, Kormany, William, Topp, Max S.
Publicado no Blood Adv (2018)

Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus

Por Koelle, David M., Liu, Zhi, McClurkan, Christopher M., Topp, Max S., Riddell, Stanley R., Pamer, Eric G., Johnson, Andrew S., Wald, Anna, Corey, Lawrence
Publicado em 2002

Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3(+) regulatory T cells in humans and mice

Por Bedke, Tanja, Iannitti, Rossana G, De Luca, Antonella, Giovannini, Gloria, Fallarino, Francesca, Berges, Carsten, Latgé, Jean-Paul, Einsele, Hermann, Romani, Luigina, Topp, Max S
Publicado em 2014

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

Por Rasche, Leo, Duell, Johannes, Castro, Inês C., Dubljevic, Valentina, Chatterjee, Manik, Knop, Stefan, Hensel, Frank, Rosenwald, Andreas, Einsele, Hermann, Topp, Max S., Brändlein, Stephanie
Publicado no Haematologica (2015)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Por Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S., Gökbuget, Nicola, Baeuerle, Patrick A., Kufer, Peter, Wolf, Andreas, Klinger, Matthias
Publicado no Exp Hematol Oncol (2017)

Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo

Por Xue, Shao-An, Gao, Liquan, Ahmadi, Maryam, Ghorashian, Sara, Barros, Rafael D, Pospori, Constandina, Holler, Angelika, Wright, Graham, Thomas, Sharyn, Topp, Max, Morris, Emma C, Stauss, Hans J.
Publicado em 2013

Immune Responses of Human Immature Dendritic Cells Can Be Modulated by the Recombinant Aspergillus fumigatus Antigen Aspf1

Por Ok, Michael, Latgé, Jean Paul, Baeuerlein, Carina, Ebel, Frank, Mezger, Markus, Topp, Max, Kurzai, Oliver, Killian, Doreen, Kapp, Markus, Grigoleit, Goetz-Ulrich, Sennefelder, Helga, Arroyo, Javier, Einsele, Hermann, Loeffler, Juergen
Publicado em 2009

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia

Por Subklewe, Marion, Topp, Max, Krupka, Christina, Kufer, Peter, Kischel, Roman, Köhnke, Thomas, Baeuerle, Patrick, Zugmaier, Gerhard, Frankel, Stanley, Maniar, Tapan, Newhall, Katie, Spiekermann, Karsten, Riethmueller, Gert, Nagorsen, Dirk, Hiddemann, Wolfgang
Publicado no J Immunother Cancer (2014)

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells

Por Reusch, Uwe, Duell, Johannes, Ellwanger, Kristina, Herbrecht, Carmen, Knackmuss, Stefan HJ, Fucek, Ivica, Eser, Markus, McAleese, Fionnuala, Molkenthin, Vera, Le Gall, Fabrice, Topp, Max, Little, Melvyn, Zhukovsky, Eugene A
Publicado no MAbs (2015)

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Por Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A., Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver G., Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S., Bargou, Ralf
Publicado no Haematologica (2017)

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Por Offner, Fritz, Samoilova, Olga, Osmanov, Evgenii, Eom, Hyeon-Seok, Topp, Max S., Raposo, João, Pavlov, Viacheslav, Ricci, Deborah, Chaturvedi, Shalini, Zhu, Eugene, van de Velde, Helgi, Enny, Christopher, Rizo, Aleksandra, Ferhanoglu, Burhan
Publicado no Blood (2015)

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Por Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, Pogge von Strandmann, Elke, Borchmann, Peter, Engert, Andreas
Publicado no Blood (2015)

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Por Zugmaier, Gerhard, Gökbuget, Nicola, Klinger, Matthias, Viardot, Andreas, Stelljes, Matthias, Neumann, Svenja, Horst, Heinz-A., Marks, Reinhard, Faul, Christoph, Diedrich, Helmut, Reichle, Albrecht, Brüggemann, Monika, Holland, Chris, Schmidt, Margit, Einsele, Hermann, Bargou, Ralf C., Topp, Max S.
Publicado no Blood (2015)

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Por Gökbuget, Nicola, Dombret, Hervé, Bonifacio, Massimiliano, Reichle, Albrecht, Graux, Carlos, Faul, Christoph, Diedrich, Helmut, Topp, Max S., Brüggemann, Monika, Horst, Heinz-August, Havelange, Violaine, Stieglmaier, Julia, Wessels, Hendrik, Haddad, Vincent, Benjamin, Jonathan E., Zugmaier, Gerhard, Nagorsen, Dirk, Bargou, Ralf C.
Publicado no Blood (2018)